Evgen Pharma PLC Issue of Equity and Total Voting Rights (3690P)
August 31 2017 - 2:01AM
UK Regulatory
TIDMEVG
RNS Number : 3690P
Evgen Pharma PLC
31 August 2017
For immediate release 31 August 2017
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Issue of Equity and Total Voting Rights
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces that it has received notice to exercise
options over 837,600 ordinary shares in the Company.
The options were granted under individual option agreements and
have exercise prices of 5 pence per share in respect of 628,000
options and 0.875 pence per share in respect of 209,600 options.
Accordingly, the Company has issued and allotted 837,600 new
ordinary shares of 0.25 pence each ("New Ordinary Shares"). The New
Ordinary Shares rank pari passu with the Company's existing issued
ordinary shares. Application has been made to admit the New
Ordinary Shares to trading on AIM and dealings in these shares are
expected to commence at 8.00 a.m. on 6 September 2017.
There are no shares held in treasury, therefore following the
admission of the New Ordinary Shares the total number of voting
rights in the Company will be 74,110,191. This figure may be used
by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest under the
Disclosure and Transparency Rules.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
Dr Stephen Franklin, CEO 5000
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Cowles, Stephanie +44 (0) 20 7466
Watson 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney
(Corporate Finance)
John Howes, Rob Rees (Corporate +44 (0) 20 3861
Broking) 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEFBLLXDVFFBBD
(END) Dow Jones Newswires
August 31, 2017 02:01 ET (06:01 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024